Compare PDLB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | ADCT |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.1M | 136.1M |
| IPO Year | 2021 | 2019 |
| Metric | PDLB | ADCT |
|---|---|---|
| Price | $20.30 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 63.0K | ★ 1.5M |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 30.86 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $28.58 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $13.91 | $0.78 |
| 52 Week High | $21.10 | $4.98 |
| Indicator | PDLB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 46.52 |
| Support Level | $19.66 | $0.98 |
| Resistance Level | $20.81 | $1.20 |
| Average True Range (ATR) | 0.38 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 47.83 | 25.00 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).